MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-06-30, IGMS had $3,987K increase in cash & cash equivalents over the period. -$83,340K in free cash flow.

Cash Flow Overview

Change in Cash
$3,987K
Free Cash flow
-$83,340K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-06-30
Stock-based compensation expense
8,200
Other
0
Net income (loss)
44,692
Prepaid expenses and other current assets
-5,915
Other non-current liabilities
-366
Other non-current assets
-244
Lease liabilities, net
-32,654
Deferred revenue
-144,122
Accrued liabilities
-23,221
Accounts payable
1,445
Depreciation
2,713
Net accretion of discounts on marketable securities
1,254
Termination of prepaid contracts and other costs
915
Purchase of net (premiums) discounts on marketable securities
307
Non-cash lease expense
1,603
Impairment and disposal of long-lived assets
52,889
Net cash used in operating activities
-83,308
Proceeds from sales of property, plant and equipment
2,372
Proceeds from maturities and sales of marketable securities
101,122
Purchase of property, plant and equipment
32
Purchases of marketable securities
16,184
Net cash provided by investing activities
87,278
Proceeds from purchases under the employee stock purchase plan
4
Proceeds from exercise of stock options
13
Payment of employee taxes and exercise costs for shares withheld
0
Payment of deferred offering costs
0
Net cash provided by financing activities
17
Net increase (decrease) in cash, cash equivalents, and restricted cash
3,987
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

IGM Biosciences, Inc. (IGMS)

IGM Biosciences, Inc. (IGMS)